Hot Features
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is ... Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 8.81 | 40.4871323529 | 21.76 | 31 | 19.4275 | 2585563 | 21.55122728 | CS |
| 4 | 7.37 | 31.7672413793 | 23.2 | 31 | 19.342 | 2875356 | 21.72003914 | CS |
| 12 | 12.93 | 73.2993197279 | 17.64 | 31 | 17.47 | 2906653 | 22.13624262 | CS |
| 26 | 20.78 | 212.257405516 | 9.79 | 31 | 8.3 | 2993528 | 16.86055494 | CS |
| 52 | 26.12 | 586.966292135 | 4.45 | 31 | 3.77 | 2824513 | 12.31097433 | CS |
| 156 | 26.88 | 728.455284553 | 3.69 | 31 | 1.03 | 1758593 | 9.38613562 | CS |
| 260 | 20.96 | 218.106139438 | 9.61 | 31 | 1.03 | 1180888 | 9.21574864 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.